Merck & Co. (MRK) : Candriam Luxembourg S.c.a. reduced its stake in Merck & Co. by 32.75% during the most recent quarter end. The investment management company now holds a total of 396,760 shares of Merck & Co. which is valued at $23,250,136 after selling 193,206 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.Merck & Co. makes up approximately 0.59% of Candriam Luxembourg S.c.a.’s portfolio.
Other Hedge Funds, Including , Genesee Valley Trust Co boosted its stake in MRK in the latest quarter, The investment management firm added 670 additional shares and now holds a total of 26,192 shares of Merck & Co. which is valued at $1,534,851. Merck & Co. makes up approx 1.00% of Genesee Valley Trust Co’s portfolio.Guinness Asset Management Ltd boosted its stake in MRK in the latest quarter, The investment management firm added 22,050 additional shares and now holds a total of 101,300 shares of Merck & Co. which is valued at $5,936,180. Merck & Co. makes up approx 1.62% of Guinness Asset Management Ltd’s portfolio.Sanders Morris Harris reduced its stake in MRK by selling 21,165 shares or 82.27% in the most recent quarter. The Hedge Fund company now holds 4,561 shares of MRK which is valued at $267,275. Merck & Co. makes up approx 0.07% of Sanders Morris Harris’s portfolio.Oakbrook Investments reduced its stake in MRK by selling 20,122 shares or 3.94% in the most recent quarter. The Hedge Fund company now holds 491,132 shares of MRK which is valued at $28,888,384. Merck & Co. makes up approx 1.54% of Oakbrook Investments’s portfolio.Carlton Hofferkamp Jenks Wealth Management boosted its stake in MRK in the latest quarter, The investment management firm added 65 additional shares and now holds a total of 29,560 shares of Merck & Co. which is valued at $1,737,832. Merck & Co. makes up approx 1.33% of Carlton Hofferkamp Jenks Wealth Management’s portfolio.
Merck & Co. opened for trading at $59.01 and hit $59.2 on the upside on Friday, eventually ending the session at $58.66, with a gain of 0.39% or 0.23 points. The heightened volatility saw the trading volume jump to 84,91,237 shares. Company has a market cap of $162,372 M.
On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $0.91. The company had revenue of $9844.00 million for the quarter, compared to analysts expectations of $9782.80 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.
Investors should note that on Jul 26, 2016, Merck & Co. announced a cash dividend of $0.4600. The company’s management has announced Sep 13, 2016 as the ex-dividend date and fixed the record date on Sep 15, 2016. The payable date has been fixed on Oct 7, 2016.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.